Find out why $VICA could see Another +60pct Move... TOMORROW!=====================
VICA (Rafina Innovations Inc.)
Current Price: $0.3150
Float: 3.91M
Chart Analysis
Website | Recent News
========================
Members,
A fresh trading week is upon us, and we have identified the perfect pick to kick it off with.
Please turn your immediate attention to VICA (Rafina Innovations Inc.).
Just like many of our recent winners, VICA trades on the OTC-QB, and has a tiny float of just 3.91M
This is an exciting time for VICA, as the Company has gone through a rebranding period in order to better reflect their business objectives.
Their revolutionary Flexisense™ technology has found demand for applications in many more industry sectors than was initially anticipated, and their portfolio of technologies have grown to include a much broader scope of innovations with application across numerous fields, including many outside the medical technology segment.
In addition to healthcare technology, VICA is currently involved with projects related to Human Augmentation, Automotive safety and Smart Homes.
One such project could be a game-changer in a multi-billion dollar market.
VICA is currently developing cutting prototype for sleep apnoea through a biPAP machine that the Company's management believes can positively impact those with sleep apnoea, a respiratory failure which occurs during sleep.
We see this as a major revenue generating opportunity for VICA.
The sleep apnoea devices market is projected to reach USD 6.49 Billion by 2023 from an estimated USD 4.44 Billion in 2018, at a CAGR of 7.8%!
VICA is another one of those tickers that could go viral in minutes, and has a history of tremendous single-day breakouts.
In fact, just last week it ran up nearly +60% in just one session.
We've done our own chart analysis, and see the potential for a move of up to +195%.
This has the potential to be the next big winner for our members, and we want to see everyone on board.
As such, we are urging all members to read our full profile on VICA, start their research now, and to add it to the top of their watchlist!
About Rafina Innovations Inc.
Rafina Innovations Inc. operates two fully owned subsidiaries: 1. HCi Viocare Technologies: developing hardware solutions aiming to empower the user by providing on demand information and enhancing living quality. The R&D center located in Glasgow, Scotland, is working on a large portfolio of cutting edge, revolutionary and disruptive technologies in the fields of Digital Health, Prosthetics, Orthotics, Diabetes, Assistive Devices, Sports & Wellbeing, and DVT. The Company has developed a unique sensing technology with the brand name Flexisense™, which uses a multitude of micro sensors to detect pressure as well as shear that is unique over other sensing technologies. The sensors are wirelessly connected to smart devices providing real time and on demand information. HCi Viocare Technologies works on a licensing business model. 2. HCi Viocare Clinics: creating the first cross-border independent chain of Prosthetics & Orthotics (P&O) and Diabetic Foot clinics in Europe.
HCi Viocare’s Glasgow clinic is a subsidiary of HCi Viocare. Its founders Sotiris Leontaritis, a highly experienced entrepreneur and Dr Christos Kapatos, a Prosthetics and Orthotics expert and inventor, share a vision to improve people’s wellbeing in the face of a growing and correlated population of the obese, diabetic, amputated and/or movement impaired. To this end, HCi Viocare is establishing a chain of Prosthetic, Orthotic and diabetic foot rehabilitation centres in addition to implementing bioengineering innovations research and development in view of gaining licensing for health and wellness sectors.
This Glasgow clinic, the only private P&O clinic in Scotland, is HCi Viocare’s first. It has evolved from the private practice of Bill Spence CPO, MBAPO, MISPO Certified Prosthetist Orthotist, founder and former chairman of the Association of Prosthetists and Orthotists (now BAPO) and former Chief of Research in Blatchford’s Clinical Services. Mr Spence played an integral role in the set-up of the rehabilitation suite and workshop, and hand-picked the P&O team responsible for client care.
The clinic will serve as a key reference point and training centre for the HCi Viocare group of clinics, exporting British and International standards of care to under-served regions in the Mediterranean and Middle East. With a view to ensuring excellent practices and care, the company is supported by Professor Stephan Solomonidis, Bioengineer, F.I.MechE at the University of Strathclyde who, during his longstanding research and academic career has substantially contributed to the P&O International standards. Both Mr Spence and Prof Solomonidis supervised the company’s co-founder Dr Kapatos in obtaining his PhD at the University of Strathclyde, a globally renowned centre of excellence in bio-engineering.
Please visit:
www.rafinainnovations.com
www.hci-viocare.co.uk
Recent Developments for VICA
Rafina Innovations Begins Development on a Prototype for Sleep Apnoea
On February 14th, the Company announced that it recently commenced development on a prototype for sleep apnoea through a biPAP machine that management believes can positively impact those with sleep apnoea, a respiratory failure which occurs during sleep.
Constantinos Zertalis, Rafina’s Chairman, President and CEO, commented: "Our research shows that 1 in 6 people suffer from respiratory failure that requires a biPAP machine. Further, solutions currently in the marketplace include equipment that tends to be large in size. Following investigation into the marketspace and needs of the consumer, our research and development team believe we can produce biPAP equipment that can be small in size, travel friendly and also energy efficient. Management expects the prototype to be ready between three to six months, and approximately the same size as a mobile phone. We believe our vision of this essential product will be attractive to the current market due to its small size, without sacrificing functionality, making it extremely convenient for users.”
Market Outlook:
The sleep apnoea devices market is projected to reach USD 6.49 Billion by 2023 from an estimated USD 4.44 Billion in 2018, at a CAGR of 7.8%. Growth in this market can primarily be attributed to factors such as the increasing prevalence of sleep apnoea globally owing to the increase of lifestyle diseases like obesity, initiatives by market players and the government to increase awareness regarding sleep apnoea, and the various technological advancements brought about by players to make the products comfortable for patients and thus increase patient compliance and adherence to the treatment.
Technical Analysis:
We love these low-float alerts, and their potential to breakout for monster single-day gains.
Last week we watched VICA jump nearly +60% in just one session.
Shares of VICA ran up from $0.24 to $0.38 last Thursday on light trade volume.
With its low-float of just 3.91M, a nice boost in volume could send shares of VICA soaring ever higher than what we witnessed last Thursday.
VICA was trading at over $1.00 less than 6-months ago.
A run back to a dollar from today's alert price would show traders gains of over +212%!
As we've mentioned above, we've done our own chart analysis, and see the potential for a move of up to +195%.
We are anticipating another huge day for VICA tomorrow.
This has the potential to be the next triple-digit gainer for our members.
As such, we are urging all members to start their research on VICA, and to add it to the top of their watchlist!
Best Regards,
The TopMarketGainers Team
Don't Miss Our Next Huge Winner...
Text 'GAINS' to '67076'
to have our Trade Alerts
Delivered Direct
to your Cell Phone.
(There is no charge.
Msg&data rates may apply.)
Follow Us On Twitter:
twitter.com
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned herewithin, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated ten thousand dollars by s 3rd party to conduct investor relations advertising and marketing for VICA. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
